Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists
Menée à partir de dossiers médicaux électroniques portant sur 1,6 million de patients atteints de diabète de type 2 (âge moyen : 62,5 ans ; 46,9 % de femmes), cette étude analyse le risque de cancer hématologique en fonction du traitement antidiabétique (GLP-1RA, metformine ou insuline)
Type 2 diabetes (T2D) and obesity have been identified as independent risk factors for various cancers, including hematologic cancers.1 Glucagon-like peptide–1 receptor agonists (GLP-1RA) have emerged as an effective treatment, offering glycemic control, weight reduction,2 and immune modulation,3 and are associated with lower cancer risk, specifically solid tumors.4 However, the association of GLP-1RA with hematologic cancers remains unexplored. This study aims to compare the risks of hematologic cancers in patients with T2D treated with GLP-1RA compared with metformin and insulin.
JAMA Network Open 2024